Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABOSTO:MCAP +0.95%76 EV-to-EBIT is 22.49 as of Aug. 09, 2026, which is 20% below its 10-year median of 28.24. GuruFocus rates OSTO:MCAP with a GF Score™ of 76/100 and a GF Value™ of kr573.86 (Fairly Valued). Among 472 Medical Devices & Instruments companies, MedCap AB ranks worse than 59.53% on this metric.
The historical rank and industry rank for MedCap AB's EV-to-EBIT or its related term are showing as below:
OSTO:MCAP'
s EV-to-EBIT Range Over the Past 10 Years
Min: 15.91 Med: 28.24 Max: 160.06
Current: 22.49
During the past 13 years, the highest EV-to-EBIT of MedCap AB was 160.06. The lowest was 15.91. And the median was 28.24.
OSTO:MCAP's EV-to-EBIT is ranked worse than 59.53% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.02
vs OSTO:MCAP: 22.49
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
MedCap AB's Enterprise Value for the quarter that ended in Jun. 2026 was kr8,028 Mil.
MedCap AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr363 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedCap AB EV-to-EBIT Related Terms
MedCap AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for MedCap AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MedCap AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where MedCap AB's EV-to-EBIT falls into.
MedCap AB's current Enterprise Value is kr8,155 Mil.
MedCap AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr363 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedCap AB (OSTO:MCAP) has a EV-to-EBIT of 22.49 as of Aug. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MedCap AB and its competitors. This is 20% below median its historical median of 28.24. Over the past decade, MedCap AB's EV-to-EBIT has ranged from 15.91 to 160.06. According to the industry distribution chart, MedCap AB ranks #281 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 59.5%.
Is MedCap AB's EV-to-EBIT too high?
MedCap AB's current EV-to-EBIT of 22.49 is 20% below median its 10-year median of 28.24. Over the past 10 years, this metric has ranged from a low of 15.91 to a high of 160.06. The Medical Devices & Instruments industry median EV-to-EBIT is 19.02. MedCap AB's value of 22.49 is 18.2% above this industry median. Based on the distribution chart, MedCap AB ranks #281 out of 472 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MedCap AB has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #281 out of 472 companies for EV-to-EBIT. This places MedCap AB in the lower half of its industry. The industry median EV-to-EBIT is 19.02. MedCap AB's value of 22.49 is 18.2% above this benchmark. Historically, MedCap AB's own EV-to-EBIT has ranged from 15.91 to 160.06 over the past decade. While the company's 10-year median is 28.24 vs. the industry median of 19.02, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.02, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current EV-to-EBIT of 22.49 is 18.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current EV-to-EBIT is 22.49, which is 20% below median its own 10-year median of 28.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr573.86, compared to a current price of kr533.00 — trading 7.1% below its estimated fair value. The current EV-to-EBIT is 22.49, which is 20% below median its 10-year median of 28.24 and 18.2% above the Medical Devices & Instruments industry median of 19.02. MedCap AB's overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current EV-to-EBIT is 22.49 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (OSTO:MCAP) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr533.00 is trading 7.1% below its estimated GF Value™ of kr573.86.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for OSTO:MCAP:
EV-to-EBIT: 22.49 (20% below median its 10-year median of 28.24)
GF Value™: kr573.86 vs. price of kr533.00 (7.1% below fair value)
Industry Position: 18.2% above the Medical Devices & Instruments median (#281 of 472)
No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
76GF Score
Get the complete analysis for OSTO:MCAP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MCAP has been successfully added to your 
